<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively analyzed 126 <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients aged &gt; or =60 years who had <z:hpo ids='HP_0000001'>all</z:hpo> been referred to the same hematological department between 1989 and 1999 </plain></SENT>
<SENT sid="1" pm="."><plain>In 76 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cases, 53 patients (median age, 72 years) were treated with combination chemotherapy (CT) for remission induction </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission (CR) rate was 57.1% </plain></SENT>
<SENT sid="3" pm="."><plain>The median overall survival (OS) was 16 months, and the rate of 3-year OS was 28% </plain></SENT>
<SENT sid="4" pm="."><plain>The favorable prognostic factors were performance status &lt; or =2, cholinesterase &gt; or =100 IU, and intermediate or favorable karyotype (P &lt; .01) </plain></SENT>
<SENT sid="5" pm="."><plain>Seventeen patients (median age, 78 years) with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular bone marrow</z:e> or poor general condition were treated with low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LDAraC) </plain></SENT>
<SENT sid="6" pm="."><plain>In these patients, the CR rate was 50% and the median OS was 11 months, with an OS estimate at 3 years of 14% </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular bone marrow</z:e> who received LDAraC for 21 days achieved CR </plain></SENT>
<SENT sid="8" pm="."><plain>In 50 patients who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 22 patients (median age, 74 years) were treated with CT, and 14 (median age, 74 years) patients were treated with LDAraC </plain></SENT>
<SENT sid="9" pm="."><plain>The CR rates were 22.7% and 21.4%, respectively, and the median OS durations were 8 months and 11 months, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>There were no significant factors that would indicate a good prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
</text></document>